Vir Biotechnology Sets $10.00 Price For $150 Million Sale Of New Shares
Vir expects approximately $140.4 million after costs, with additional proceeds possible if underwriters exercise their option.
Vir Biotechnology, which develops medicines for serious infectious diseases and cancer, priced a $150 million stock offering Thursday at $10.00 a share. The company expects approximately $140.4 million after fees and expenses, according to its SEC 8-K filed Friday.
New Shares, Cash After Costs
Vir is selling 15 million common shares itself, so the proceeds go to the drug developer. Issuing new shares expands the share count and reduces existing holders' proportional ownership.
The underwriters can buy additional shares—up to 2.25 million—during a 30-day option period at the same offering price. Vir expects approximately $161.5 million in net proceeds if that option is exercised in full.
Leerink Partners, Morgan Stanley and Evercore ISI are leading the offering. Raymond James is serving as co-manager.
A Portfolio Still In Development
Vir's medicines remain candidates in development and have not been approved for sale. Its clinical portfolio includes chronic hepatitis delta programs and T-cell engager programs for solid tumors; other cancer programs remain in preclinical development.
The company holds exclusive rights to PRO-XTEN, a masking platform for cancer and infectious-disease programs. The trademark belongs to Amunix Pharmaceuticals, a Sanofi company.
Vir also uses dAIsY, its artificial-intelligence engine, to develop and engineer next-generation antibodies. Its portfolio includes elebsiran, and it has taken on regulatory sponsorship of all current T-cell engager trials.
Collaboration and licensing agreements are another part of the business. Vir brings in technologies and medicine candidates from other companies, while licensing selected candidates out for further development and possible commercialization.
Thursday's Proposal Reached Pricing
Vir announced the proposed sale Thursday and set its size and price that same day. The proposal had left the offering's terms dependent on market and other conditions; the priced transaction now specifies the shares and expected proceeds.
Vir expects the sale to close Monday.
Sources
- 8-K Filing — Vir Biotechnology, Inc. (VIR) — SEC EDGAR
- Exhibit d156106dex991.htm — Vir Biotechnology, Inc. 8-K exhibit — SEC EDGAR
- Exhibit d156106dex992.htm — Vir Biotechnology, Inc. 8-K exhibit — SEC EDGAR
- Vir Biotechnology Announces Proposed Public Offering — businesswire.com